For a long time, there was only one option for treating skin melanoma in adjuvant mode - recombinant interferon alpha drugs. The emergence of anti-CTLA-4-, anti-PD-l-inhibitors and targeted therapy marked the beginning of a new era of the disease effective treatment. Thanks to modern methods of systemic therapy, the rates of relapse-free survival have significantly increased compared to similar indicators that were observed ten years ago. The article provides the analysis of the results of studies of adjuvant therapy of stages II-IV after complete cytoreduction, and highlights the latest clinical recommendations.
|Translated title of the contribution||ADJUVANT THERAPY OF SKIN MELANOMA|
|State||Published - 2020|
- adjuvant therapy
- targeted therapy